Bladder Cancer Innovations In Immunotherapy And Targeted Treatments

Original Article

Abstract

Background: Bladder cancer is common worldwide and risk increases when people smoke tobacco or handle chemicals at work. The current medical approach through surgery and chemotherapy struggles with patients seeing continued return of cancer and increased severity. Modern targeted medicine and immunotherapy help doctors create specific treatments that improve how patients recover from their conditions.

Objectives: To evaluate the safety and effectiveness of targeted therapies and immunotherapy in the treatment of bladder cancer, with a focus on reducing cancer recurrence and progression while enhancing overall patient outcomes.

Study Design : A Cross Sectional Study.

Place And Duration Of Study. Department of Nephrology Mercy Teaching Hospital Peshawar from jan 2019 to jan 2020

Methods: The research took place at Mercy Teaching Hospital Peshawar during a one-year period spanning from January 2019 through January 2020. The researcher included 150 patients through consecutive sampling. The researchers obtained information about patient demographics together with clinical data and laboratory results. The researchers utilized SPSS version 24.0 to conduct statistical procedures which mainly involved descriptive and comparative statistics.

Results:120 bladder cancer patients into three treatment groups with 45 patients using immunotherapy, 45 using targeted therapy, and 30 getting standard treatment. The patients who received immunotherapy experienced a PFS at 12.3±2.1 months which proved statistically superior to the control group's PFS of 7.4±1.8 months (p<0.01). Targeted therapy achieved a 45% response rate that proved better than the standard control group's 25% rate (p<0.05). Patients in all treatment groups reported minor side effects that medical teams could control effectively.

Conclusion: Bladder cancer patients using immunotherapy and targeted therapy treatment show improved survival rates and have better chances of tumor clearance than patients receiving standard therapies. We should add personalized treatment options to standard care plans because each patient's medical profile requires unique attention to get better treatment results.

Keywords: Bladder cancer, immunotherapy, targeted therapy, treatment outcomes, patient survival